

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 8-K

November 26, 2003

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of the earliest event reported): November 25, 2003

---

**Valeant Pharmaceuticals International**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization)

1-11397  
(Commission File Number)

33-0628076  
(I.R.S. Employer  
Identification No.)

3300 Hyland Avenue  
Costa Mesa, California 92626  
(Address of principal executive offices) (Zip Code)

(714) 545-0100  
(Registrant's telephone number, including area code)

---

---

---

**TABLE OF CONTENTS**

Item 7. Financial Statements and Exhibits.

Item 9. Regulation FD Disclosure.

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

EXHIBIT 99.4

EXHIBIT 99.5

---

**Table of Contents****Item 7. Financial Statements and Exhibits.**

(c) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated November 25, 2003.
99.2	Information contained under the caption <b>Risk Factors</b> of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.3	Information contained under the caption <b>Selected Consolidated Financial and Other Data</b> of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.4	Information contained under the caption <b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b> of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.5	Information contained under the caption <b>Business</b> of the registrant's preliminary Offering Memorandum dated November 25, 2003.

**Item 9. Regulation FD Disclosure.**

On November 25, 2003, Valeant Pharmaceuticals International (the **Company**) issued a press release announcing its intention to offer, subject to market and other conditions, up to \$275 million principal amount of Senior Notes due 2011 (the **Notes**) (A) to qualified institutional buyers in an offering exempt from registration pursuant to Rule 144A under the Securities Act of 1933 and (B) outside the United States to persons other than U.S. Persons in reliance upon Regulation S under the Securities Act of 1933. The November 25, 2003 press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

The information contained under the captions **Risk Factors**, **Selected Consolidated Financial and Other Data**, **Management's Discussion and Analysis of Financial Condition and Results of Operations** and **Business** in the **Company's** preliminary Offering Memorandum dated November 25, 2003, to be used in connection with the offer and sale of the Notes, is attached as Exhibits 99.2, 99.3, 99.4, and 99.5, respectively, to this report and is incorporated herein by this reference.

The information in this Current Report on Form 8-K, including the exhibits thereto, will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the **Exchange Act**) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 25, 2003

VALEANT PHARMACEUTICALS INTERNATIONAL

By /s/ BARY G. BAILEY

---

Bary G. Bailey,  
Executive Vice President and Chief  
Financial Officer

-3-

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated November 25, 2003.
99.2	Information contained under the caption Risk Factors of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.3	Information contained under the caption Selected Consolidated and Other Financial Data of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.4	Information contained under the caption Management's Discussion and Analysis of Financial Condition and Results of Operations of the registrant's preliminary Offering Memorandum dated November 25, 2003.
99.5	Information contained under the caption Business of the registrant's preliminary Offering Memorandum dated November 25, 2003.